← Institutional research
Maps · Clinical development
Cancer vaccine landscape
The programmes, clinical evidence and organisations shaping cancer vaccination.
The 1,730 product entries represent 1,679 distinct programmes or preparations. Multiple product entries can refer to one programme. Each chart states its counting unit, and a programme can appear in more than one clinical setting or cancer type.
Cancer-vaccine programmes by indication
Clinical intent by development stage
Sponsor / developer countries
Trials by sponsor type
Trial status by phase
Prevention targets
Interception targets
Therapeutic cancer types
Top 20 organisations running trials
Programme catalogue
PreviewFirst five programme previews
| Vaccine / programme | Sponsor / developer | Country | Setting | Platform | Highest phase |
|---|---|---|---|---|---|
| Autogene cevumeran | BioNTech / Genentech (Roche) | Germany | Therapeutic | RNA vaccine | Phase II |
| ELI-002 | Elicio Therapeutics | United States | Therapeutic | Peptide vaccine | Phase II |
| Intismeran autogene (V940; mRNA-4157) | Moderna / Merck (MSD) | United States | Therapeutic | RNA vaccine | Phase III |
| Sipuleucel-T | Dendreon | United States | Therapeutic | Dendritic-cell vaccine | Approved |
| BNT111 | BioNTech SE | Germany | Therapeutic | RNA vaccine | Phase II |
Checking your access…